Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07753174

A Clinical Trial to Evaluate the Effects of an Omega-3-containing Supplement on DHA and EPA Levels in the Blood

This is a 12-week, hybrid, single-arm clinical trial designed to evaluate the effects of an omega-3-containing supplement (Omega Active) on DHA and EPA levels in the blood. Forty participants will take two capsules of the test product daily and complete study-specific questionnaires at Baseline, Week 4, Week 8, and Week 12, while also attending their local Quest Diagnostics Center at Baseline and Week 12 for blood biomarker testing.

The study will also assess participants' perceptions of the effects of the test product on cognitive performance, gastrointestinal symptoms, and overall health through self-reported questionnaires. There is no randomization or blinding; all participants will receive the active supplement for the full 12-week intervention period.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Omega-3 Deficiency Cardiovascular Health Cognitive Health DHA and EPA Blood Levels

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Citruslabs

Las Vegas, Nevada, 89101, United States

Location status: Recruiting

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Be male or female.
  • Be aged 18-65.
  • Anyone in good general health.
  • Willing to avoid taking other supplements, prescription medications, or herbal remedies that target DHA or EPA levels in the body, for the duration of the study.
  • Must not have taken fish oil or plant-based omega oil supplements in the past eight weeks.
  • Willing to maintain their current diet, sleep schedule, and activity level for the duration of the study.
  • Resides in the United States.

Exclusion criteria

  • Anyone with pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders.
  • Anyone on anticoagulants or antiplatelet therapy.
  • Anyone with a bleeding disorder.
  • Anyone with any allergies or sensitivities to any of the study product ingredients.
  • Any women who are pregnant, breastfeeding, or trying to conceive (or who will be at any point during the study period).
  • Anyone unwilling to follow the study protocol.
  • Anyone who does not consume any specific dietary ingredients for any reason.
  • Currently partaking in another research study or will be partaking in any other research study at any point during this study's duration.

Treatment and study plan

Omega Active Supplement

Dietary Supplement

All participants receive one dose (two capsules) of the Omega Active omega-3 supplement daily for 12 weeks.

Primary outcomes

  1. Change in DHA levels in the blood

    Time frame: Baseline and Week 12

    Change from Baseline in DHA blood concentration as assessed by blood biomarker testing (test code 92701) at Quest Diagnostics Center

  2. Change in EPA levels in the blood

    Time frame: Baseline and Week 12

    Change from Baseline in EPA blood concentration as assessed by blood biomarker testing (test code 92701) at Quest Diagnostics Center

Secondary outcomes

  1. Change in self-reported cognitive performance

    Time frame: Baseline, Week 4, Week 8, and Week 12

    Participant-reported perceptions of the effects of the test product on cognitive function as assessed by self-reported questionnaire

  2. Change in self-reported gastrointestinal symptoms

    Time frame: Baseline, Week 4, Week 8, and Week 12

    Participant-reported occurrence of gastrointestinal symptoms, including acid reflux, as assessed by self-reported questionnaire

  3. Change in self-reported overall health and well-being

    Time frame: Baseline, Week 4, Week 8, and Week 12

    Participant-reported perceptions of overall health and well-being as assessed by self-reported questionnaire

  4. Participant experience with consumption of the test product

    Time frame: Baseline, Week 4, Week 8, and Week 12

    Participant-reported experience of consuming the test product, including palatability and taste, as assessed by self-reported questionnaire

Study contacts

Contact information is provided by the study sponsor or research team.

Patrick Renner

CONTACT

4242450284

Sponsors and collaborators

Lead sponsor

Revive Active

Industry

Collaborators

  • Citruslabs

Registry information

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Aug 7, 2026
Registry last updated
Aug 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.